Limits...
Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography.

Mori T, Onimaru R, Onodera S, Tsuchiya K, Yasuda K, Hatakeyama H, Kobayashi H, Terasaka S, Homma A, Shirato H - Radiat Oncol (2015)

Bottom Line: The 5-year overall survival (OS) and relapse-free survival (RFS) rates were estimated at 88% and 74%, respectively.Five patients with stage C disease had recurrence with the median time to recurrence of 59 months (range 7-115 months).Late adverse events equal to or above Grade 2 in CTCAE v4.03 were observed in three patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Hokkaido University Hospital, Sapporo, Japan. tamori-tym@umin.ac.jp.

ABSTRACT

Background: Olfactory neuroblastoma (ONB) is a rare tumor originating from olfactory epithelium. Here we retrospectively analyzed the long-term treatment outcomes and toxicity of radiotherapy for ONB patients for whom computed tomography (CT) and three-dimensional treatment planning was conducted to reappraise the role of radiotherapy in the light of recent advanced technology and chemotherapy.

Methods: Seventeen patients with ONB treated between July 1992 and June 2013 were included. Three patients were Kadish stage B and 14 were stage C. All patients were treated with radiotherapy with or without surgery or chemotherapy. The radiation dose was distributed from 50 Gy to 66 Gy except for one patient who received 40 Gy preoperatively.

Results: The median follow-up time was 95 months (range 8-173 months). The 5-year overall survival (OS) and relapse-free survival (RFS) rates were estimated at 88% and 74%, respectively. Five patients with stage C disease had recurrence with the median time to recurrence of 59 months (range 7-115 months). Late adverse events equal to or above Grade 2 in CTCAE v4.03 were observed in three patients.

Conclusion: Multimodal therapy including radiotherapy with precise treatment planning based on CT simulation achieved an excellent local control rate with acceptable toxicity and reasonable overall survival for patients with ONB.

No MeSH data available.


Related in: MedlinePlus

Coronal view of follow-up MRI 10 years after radiotherapy (patient 1). Focal enhancement at the base of the frontal lobe was observed. This finding disappeared in follow-up MRI after 9 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4403781&req=5

Fig3: Coronal view of follow-up MRI 10 years after radiotherapy (patient 1). Focal enhancement at the base of the frontal lobe was observed. This finding disappeared in follow-up MRI after 9 months.

Mentions: Acute adverse effects such as radiation dermatitis, mucositis of nasal mucosa, and conjunctivitis were within Grade 1–2 and tolerable in all patients. One patient was affected with intracranial epidural abscess, when radiotherapy was performed till 36 Gy and radiotherapy was suspended during 13 days. One patient died 81 days after the completion of radiotherapy and one patient was followed up in another institution after the completion of radiotherapy, so 15 out of the 17 patients were eligible for long-term toxicities evaluation. Late adverse effects were observed in three patients. Three patients showed abnormal findings thought to be radiation injury at the frontal and left temporal lobes, the frontal and bilateral temporal lobes, and the left frontal lobe in follow-up brain MRI at 23, 47 and 57 months after radiotherapy, respectively, but they showed no symptoms (Figure 3).Figure 3


Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography.

Mori T, Onimaru R, Onodera S, Tsuchiya K, Yasuda K, Hatakeyama H, Kobayashi H, Terasaka S, Homma A, Shirato H - Radiat Oncol (2015)

Coronal view of follow-up MRI 10 years after radiotherapy (patient 1). Focal enhancement at the base of the frontal lobe was observed. This finding disappeared in follow-up MRI after 9 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4403781&req=5

Fig3: Coronal view of follow-up MRI 10 years after radiotherapy (patient 1). Focal enhancement at the base of the frontal lobe was observed. This finding disappeared in follow-up MRI after 9 months.
Mentions: Acute adverse effects such as radiation dermatitis, mucositis of nasal mucosa, and conjunctivitis were within Grade 1–2 and tolerable in all patients. One patient was affected with intracranial epidural abscess, when radiotherapy was performed till 36 Gy and radiotherapy was suspended during 13 days. One patient died 81 days after the completion of radiotherapy and one patient was followed up in another institution after the completion of radiotherapy, so 15 out of the 17 patients were eligible for long-term toxicities evaluation. Late adverse effects were observed in three patients. Three patients showed abnormal findings thought to be radiation injury at the frontal and left temporal lobes, the frontal and bilateral temporal lobes, and the left frontal lobe in follow-up brain MRI at 23, 47 and 57 months after radiotherapy, respectively, but they showed no symptoms (Figure 3).Figure 3

Bottom Line: The 5-year overall survival (OS) and relapse-free survival (RFS) rates were estimated at 88% and 74%, respectively.Five patients with stage C disease had recurrence with the median time to recurrence of 59 months (range 7-115 months).Late adverse events equal to or above Grade 2 in CTCAE v4.03 were observed in three patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Hokkaido University Hospital, Sapporo, Japan. tamori-tym@umin.ac.jp.

ABSTRACT

Background: Olfactory neuroblastoma (ONB) is a rare tumor originating from olfactory epithelium. Here we retrospectively analyzed the long-term treatment outcomes and toxicity of radiotherapy for ONB patients for whom computed tomography (CT) and three-dimensional treatment planning was conducted to reappraise the role of radiotherapy in the light of recent advanced technology and chemotherapy.

Methods: Seventeen patients with ONB treated between July 1992 and June 2013 were included. Three patients were Kadish stage B and 14 were stage C. All patients were treated with radiotherapy with or without surgery or chemotherapy. The radiation dose was distributed from 50 Gy to 66 Gy except for one patient who received 40 Gy preoperatively.

Results: The median follow-up time was 95 months (range 8-173 months). The 5-year overall survival (OS) and relapse-free survival (RFS) rates were estimated at 88% and 74%, respectively. Five patients with stage C disease had recurrence with the median time to recurrence of 59 months (range 7-115 months). Late adverse events equal to or above Grade 2 in CTCAE v4.03 were observed in three patients.

Conclusion: Multimodal therapy including radiotherapy with precise treatment planning based on CT simulation achieved an excellent local control rate with acceptable toxicity and reasonable overall survival for patients with ONB.

No MeSH data available.


Related in: MedlinePlus